The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats

Journal of Neural Transmission

Volumn 112, Issue 9, 2005, Pages 1213-1221

  Nissinen, E ^a,c   Nissinen, H ^a   Larjonmaa, H ^b   Vaananen A ^b   Helkamaa, T ^b   Reenila I ^b   Rauhala, P ^b  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Nonclinical R and D   (Finland)

Author keywords

COMT; Homocysteine; Levodopa; Parkinson's disease; SAM

Indexed keywords

CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; HOMOCYSTEINE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; DOSE RESPONSE; HYPERHOMOCYSTEINEMIA; MALE; METHYLATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; LEVODOPA; MALE; RATS; RATS, WISTAR;

EID: 24044535119     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-004-0262-4     Document Type: Article

References (32)

1. P Allain A Le Bouil E Cordillet L Le Quay H Bagheri JL Montastruc 1995 Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurol Toxicol 16 527 530
2. T Apeland MA Mansoor RE Strandjord O Kristensen 2000 Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. Acta Neurol Scand 101 217 223
3. F Blandini R Fancellu E Martignoni A Mangiagalli C Pacchetti A Samuele G Nappi 2001 Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease. Clin Chem 47 1102 1104
4. B Boudikova C Szumlanski B Maidak R Weinshilboum 1990 Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48 381 389
5. CJ Boushey SA Beresford GS Omenn AG Motulsky 1995 A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 1049 1057
6. L Brattstrom DE Wilcken J Ohrvik L Brudin 1998 Common methylenetetrahydro-folate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98 2520 2526
7. R Clarke L Daly K Robinson E Naughten S Cahalane B Fowler I Graham 1991 Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 1149 1155
8. K Fassbender O Mielke T Bertsch B Nafe S Fröschen M Hennerici 1999 Homocysteine in cerebral macroangiography and microangiopathy. Lancet 353 1586 1587
9. M Forsberg M Lehtonen M Heikkinen J Savolainen T Järvinen PT Männistö 2003 Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther 304 498 506
10. GJ Hankey JW Eikelboom 1999 Homocysteine and vascular disease. Lancet 354 407 413
11. W Kuhn R Roebroek H Blom D van Oppenraaij H Przuntek A Kretschmer T Buttner D Woitalla T Muller 1998 Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 40 4 225 227
12. MS Lee CH Lyoo I Ulmanen A-C Syvänen JO Rinne 2001 Genotypes of catechol-O-methyltransferase and response to levodopa in patients with Parkinson's disease. Neurosci Lett 298 131 134
13. MS Lee HS Kim EK Cho JH Lim JO Rinne 2002 COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 58 564 567
14. T Lotta J Vidgren C Tilgmann I Ulmanen K Melén I Julkunen J Taskinen 1995 Kinetics of human soluble and membrane-bound catechol-O- methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 4202 4210
15. J Ma MJ Stampfer CH Hennekens P Frosst J Selhub J Horsford MR Malinow WC Willett R Rozen 1996 Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94 2410 2416
16. JW Miller B Shukitt-Hale R Villalobos-Molina MR Nadeau J Selhub JA Joseph 1997 Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20 55 66
17. JW Miller J Selhub MR Nadeau CA Thomas RG Feldman PA Wolf 2003 Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 60 1125 1129
18. T Müller B Werne B Fowler W Kuhn 1999 Nigral endothelial dysfunction, homocysteine, and Parkinson's disease [Letter]. Lancet 354 126 127
19. T Müller D Woitala Hauptmann B Fowler W Kuhn 2001 Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 308 54 56
20. T Müller D Woitala B Fowler W Kuhn 2002 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 109 175 179
21. PT Männistö S Kaakkola 1989 New Selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10 54 56
22. E Nissinen I-B Lindén E Schultz P Pohto 1992 Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346 262 266
23. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42: 747-755
24. S Reutens P Sachdev 2002 Homocysteine in neuropsychiatric disorders of the elderly. Int J Geriatr Psychiatry 17 859 864
25. Rinne UK, Larsen JP, Siden Å, Worm-Petersen J, and the Nomecomt Study Group (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51: 1309-1314
26. 6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 97 437 443
27. JD Rogers A Sanchez-Saffon AB Frol R Diaz-Arrastia 2003 Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60 59 64
28. PM Ueland S Hustad J Schneede H Refsum SE Vollse 2001 Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22 195 201
29. FM van Bockxmeer CD Mamotte SD Vasikaran RR Taylor 1996 Methylenetetrahydrofolate reductase gene and coronary heart disease. Circulation 94 3074 3078
30. 6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 355 517 522
31. K Yasui H Kowa K Nakaso T Takeshima K Nakashima 2000 Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55 437 440
32. K Yasui K Nakaso H Kowa T Takeshima K Nakashima 2003 Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 108 66 67